Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Azilva Ranked No. 1 in Both HP, GP Markets for 2 Straight Months: Rep Track Survey
July 23, 2012
- Patent Cliff for Kipres Looms; Will Kyorin Continue to Stand Alone in Respiratory Disease Field?
July 23, 2012
- HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
- Aricept Successor BACE Inhibitor Reduced Aβ in PI Studies: Eisai
July 20, 2012
- Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
- Sandoz Initiates Voluntary Recall of Carboplatin, Shipment Suspended
July 20, 2012
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
- Alfresa HD to Make Tokiwa Yakuhin Wholly-Owned Subsidiary
July 19, 2012
- OTC Market Decreases 0.4% to 611.5 Billion Yen in 2011: Fuji-Keizai
July 19, 2012
- Eisai Ties Up with Verastem for Generation of Novel Wnt Signal Inhibitors
July 19, 2012
- Chugai, Taisho File NDA for Novel Osteoporosis Treatment
July 19, 2012
- Chugai Opens Singapore Research Subsidiary, Aims to Produce Over 5 Antibody Candidates per Year
July 18, 2012
- Nippon Kayaku Initiates PIII Study of NK105 for Breast Cancer
July 18, 2012
- Chairman Humer of Roche Criticizes Drug Pricing Policy in Japan as“Extremely Negative”
July 18, 2012
- Nippon Kayaku Launches New Specification of Generic Kytril
July 18, 2012
- China to Overtake Japan as Second-Biggest Drug Market by 2016: IMS Health
July 18, 2012
- MSD to Launch Oral Rotavirus Vaccine RotaTeq on July 20
July 18, 2012
- Janssen Applies for HIV Drug Prezista Naive Tablet 800 mg
July 17, 2012
- Otsuka HD’s Vice Chairman Otake Resigns for “Personal Reasons”
July 17, 2012
- Bioventure Industry Caught in Negative Spiral: DBJ Report
July 17, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…